Maxim Group Reaffirms Their Hold Rating on First Wave Bio (FWBI)

In a report released yesterday, Naz Rahman from Maxim Group maintained a Hold rating on First Wave Bio (FWBIResearch Report). The company’s shares closed last Friday at $1.41, close to its 52-week low of $1.27.

According to, Rahman has 0 stars on 0-5 stars ranking scale with an average return of -35.0% and a 4.3% success rate. Rahman covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Galmed Pharmaceuticals, and Vertex Pharmaceuticals.

First Wave Bio has an analyst consensus of Hold.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $26.30 and a one-year low of $1.27. Currently, First Wave Bio has an average volume of 1.61M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.

Read More on FWBI:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More